Delara Motlagh, PhD, MS, EMBA, Terumo Blood and Cell Technologies, Lakewood, CO, comments on the challenges in scaling-up cell and gene therapy manufacturing. Flexibility in the initial process development of the product is vital to make changes that may be needed in later stages of production. Dr Motlagh also emphasizes the role automation plays in expediting the manufacturing process, especially towards the final stages, as well as in facilitating regulatory approval of the therapies. Platforms that provide closed and Good Manufacturing Practice compliant systems will additionally be crucial to scale-up the commercialization of advanced therapies. This interview took place at Advanced Therapies Week 2022.
Delara Motlagh, PhD, MS, EMBA, is an employee of Terumo Blood and Cell Technologies.